6%) with a PCD and 8240 (78.4%) with a non-PCD (percutaneous angioplasty balloon and/or bare metal stent). Survival rates at 2 years (77.4% versus 79.7%) and 3 years (70.7% versus 71.8%) were similar between PCD and non-PCD groups, respectively. The adjusted hazard for all-cause mortality for patients treated with a PCD versus non-PCD was 1.06…[Read more]

PROSPERO registration ID CRD42020151106.

The implications of molecular biomarkers

1/2 mutations and

gene promoter methylation were evaluated for prognostic outcome of glioma patients.

Glioma cases were analyzed for

1/2 mutations and

promoter methylation by DNA sequencing and methylation-specific PCR,…[Read more]